NuvOx welcomes all inquiries regarding potential opportunities for collaboration or investment. Please e-mail your inquiries to John McGonigle, Business Development Associate, at jmcgonigle@nuvoxpharma.com  

pipeline partnership at NuvOx Pharma


  1. NVX-108 is designed to reduce tumor hypoxia in order to make tumors more sensitive to radiation, chemotherapy, and/or immunotherapy. It has completed enrollment in a Phase Ib/II clinical trial in glioblastoma multiforme patients receiving radiation therapy and chemotherapy. The trial showed statistically significant evidence of tumor re-oxygenation (p=0.015) with no significant change in the oxygenation of the normally oxygenated brain tissue (p=0.65). Early results show evidence of increased overall survival. The FDA has allowed an Investigational New Drug application for a Phase II clinical trial.
  2. NVX-208 is designed for acute ischemic stroke. Pre-clinical studies show that NVX-208 can reduce neurological damage by 85% when it is given 3 hours after the onset of stroke. A randomized, placebo controlled Phase Ib/II clinical trial is being supported by the University of Arkansas for Medical Sciences.
  3. NVX-508 is designed for treating acute complications of sickle cell disease. A pre-clinical study of acute chest syndrome in mice saw 0% survival in controls and 100% survival in treated animals. The FDA has allowed a Phase Ib clinical trial in collaboration with the University of Pittsburgh.
  4. NVX-308 for myocardial infarction. Studies in mice show that NVX-308 can reduce the damage to cardiac tissue from myocardial infarction by 72% when NVX-308 is given after myocardial infarction is induced. NuvOx has recently received funding from the NHLBI to study the effects of NVX-308 in a porcine model of myocardial infarction.
  5. NVX-408 is for hemorrhagic shock. Pre-clinical studies by the US Army showed 0% survival in controls and 100% survival in treated animals. NuvOx has partnered with Jiangsu Nhwa Pharmaceutical Co., Ltd., to develop the product in China – NuvOx retains rights in the rest of the world for treatment of hemorrhage.
  6. NVX-428 is for traumatic brain injury. Pre-clinical studies by the US Navy showed an increase in brain tissue oxygen tension with NVX-428 administration following traumatic brain injury in rats.